January 19, 2018 09:31 AM EST

PharmaMar stock tanks after PhIII ovarian cancer study flops

John Carroll

Editor & Founder

PharmaMar’s late-stage test of Zepsyre (lurbinectedin) has flunked the primary endpoint on progression-free survival for platinum-resistant ovarian cancer patients. And the news tanked the Spanish …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

PharmaMar stock tanks after PhIII ovarian cancer study flops

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Trump administration reveals 'most favored nation' drug price country targets

In his first major policy rollout, Vinay Prasad looks to challenge existing 'dogma' on Covid vaccines

Updated: FDA adcomm splits votes on Genentech and J&J cancer drugs

Makary, Prasad spell out FDA ground rules for future Covid vaccine approvals

RFK Jr. spars with senators over research cuts, HHS budget plan

Does your supply chain hold up under pressure for high-risk temperature-critical shipments?

Phar­ma­Mar stock tanks af­ter PhI­II ovar­i­an can­cer study flops

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

PharmaMar stock tanks after PhIII ovarian cancer study flops